Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Follows Pfizer Formula For Access To Florida Medicaid

Executive Summary

Bristol-Myers Squibb's agreement with Florida Medicaid will call for the company to spend at least $4.4 mil. on disease management programs in exchange for formulary status for all of its products.

You may also be interested in...



Florida Gets 36% Raise From Pfizer Under New Disease Management Contract

Pfizer's contract extension with Florida provides a 36% increase in savings from disease management programs over the previous agreement

Florida Disease Management Report: Programs Save 11%; Rebates Save More

Industry-sponsored disease management services have saved the Florida Medicaid program approximately 11%, according to an analysis prepared for the state legislature

Florida Disease Management Report: Programs Save 11%; Rebates Save More

Industry-sponsored disease management services have saved the Florida Medicaid program approximately 11%, according to an analysis prepared for the state legislature

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS038461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel